Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1

被引：36

作者：

Kasahara, Norimitsu ^{[1
]}

Sunaga, Noriaki ^{[2
]}

Tsukagoshi, Yusuke ^{[2
]}

Miura, Yosuke ^{[2
]}

Sakurai, Reiko ^{[3
]}

Kitahara, Shinsuke ^{[2
]}

Yokobori, Takehiko ^{[4
]}

Kaira, Kyoichi ^{[5
]}

Mogi, Akira ^{[6
]}

Maeno, Toshitaka ^{[2
]}

Asao, Takayuki ^{[1
]}

Hisada, Takeshi ^{[7
]}

机构：

[1] Gunma Univ Hosp, Innovat Med Res Ctr, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan

[2] Gunma Univ, Dept Resp Med, Grad Sch Med, Maebashi, Gunma, Japan

[3] Gunma Univ Hosp, Oncol Ctr, Maebashi, Gunma, Japan

[4] Gunma Univ, Dept Innovat Canc Ctr Immunotherapy, Maebashi, Gunma, Japan

[5] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Japan

[6] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, Maebashi, Gunma, Japan

[7] Gunma Univ, Grad Sch Hlth Sci, Maebashi, Gunma, Japan

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 03期

关键词：

Glasgow prognostic score; anti-PD1; non-small cell lung cancer; immunotherapy; biomarker; TO-LYMPHOCYTE RATIO; INFLAMMATION; NIVOLUMAB; CHEMOTHERAPY; MANAGEMENT; DOCETAXEL; OXYCODONE; CACHEXIA; OUTCOMES; INDEX;

D O I：

10.21873/anticanres.13262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: No definitive biomarker exists for predicting treatment efficacy or response to therapy with antibody to programmed cell death-1 (PD1) for patients with advanced non-small cell lung cancer (NSCLC). Hence, we investigated whether the Glasgow prognostic score (GPS) predicted anti-PD1 treatment response for advanced NSCLC. Patients and Methods: This study retrospectively identified 47 patients with NSCLC treated with anti-PD1 and assessed the prognostic value of the GPS. The GPS was calculated using C-reactive protein and albumin concentrations 1 month after starting anti-PD1 treatment. Kaplan-Meier method and Cox proportional hazard models were used to examine differences in progression-free (PFS) and overall (OS) survival, and clinical response. Results: The post-treatment GPS independently predicted anti-PD1 treatment efficacy, as a good post-treatment GPS (GPS 0-1) was significantly associated with improved PFS. Intra-treatment GPS change was associated with clinical response. Conclusion: The post-treatment GPS independently predicted efficacy of anti-PD1 treatment for NSCLC.

引用

页码：1455 / 1461

页数：7

共 37 条

[1] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[4] The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer [J].

Brown, D. J. F. ;

Milroy, R. ;

Preston, T. ;

McMillan, D. C. .

JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (06) :705-708

[5] Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab [J].

Capone, Mariaelena ;

Giannarelli, Diana ;

Mallardo, Domenico ;

Madonna, Gabriele ;

Festino, Lucia ;

Grimaldi, Antonio Maria ;

Vanella, Vito ;

Simeone, Ester ;

Paone, Miriam ;

Palmieri, Giuseppe ;

Cavalcanti, Ernesta ;

Caraco, Corrado ;

Ascierto, Paolo Antonio .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[6] Inflammation and cancer [J].

Coussens, LM ;

Werb, Z .

NATURE, 2002, 420 (6917) :860-867

[7] Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? [J].

Dajczman, Esther ;

Kasymjanova, Goulnar ;

Kreisman, Harvey ;

Swinton, Nelda ;

Pepe, Carmela ;

Small, David .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) :1133-1136

[8] Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy [J].

Eigentler, Thomas K. ;

Hassel, Jessica C. ;

Berking, Carola ;

Aberle, Jens ;

Bachmann, Oliver ;

Gruenwald, Viktor ;

Kaehler, Katharina C. ;

Loquai, Carmen ;

Reinmuth, Niels ;

Steins, Martin ;

Zimmer, Lisa ;

Sendl, Anna ;

Gutzmer, Ralf .

CANCER TREATMENT REVIEWS, 2016, 45 :7-18

[9] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].

Ferrucci, P. F. ;

Ascierto, P. A. ;

Pigozzo, J. ;

Del Vecchio, M. ;

Maio, M. ;

Cappellini, G. C. Antonini ;

Guidoboni, M. ;

Queirolo, P. ;

Savoia, P. ;

Mandala, M. ;

Simeone, E. ;

Valpione, S. ;

Altomonte, M. ;

Spagnolo, F. ;

Cocorocchio, E. ;

Gandini, S. ;

Giannarelli, D. ;

Martinoli, C. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738

[10] Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients [J].

Ferrucci, P. F. ;

Gandini, S. ;

Battaglia, A. ;

Alfieri, S. ;

Di Giacomo, A. M. ;

Giannarelli, D. ;

Cappellini, G. C. Antonini ;

De Galitiis, F. ;

Marchetti, P. ;

Amato, G. ;

Lazzeri, A. ;

Pala, L. ;

Cocorocchio, E. ;

Martinoli, C. .

BRITISH JOURNAL OF CANCER, 2015, 112 (12) :1904-1910

← 1 2 3 4 →